NEW YORK (GenomeWeb) – Rosetta Genomics reported today after the close of the market a 228 percent jump in 2014 revenues, derived primarily from the sale of its microRNA-based diagnostics.

The company's revenues from continuing operations jumped to $1.3 million last year from $405,000 the year before.

Rosetta's net loss after discontinued operations was $14.5 million, or $1.29 a share on 11.2 million shares outstanding, versus $12.9 million, or $1.34 a share, on 9.6 million shares outstanding, in 2013.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.